Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label Phase Ib Dose-escalation and Dose-confirmational Study for the Tolerability and Safety of N-hydroxy-N'-Phenyl-octanediamide (Vorinostat) in Patients With Mild Alzheimer's Disease

NCT03056495 is registered in ClinicalTrials.gov with German Center for Neurodegenerative Diseases (DZNE) as lead sponsor.

NCT NCT03056495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03056495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label Phase Ib Dose-escalation and Dose-confirmational Study for the Tolerability and Safety of N-hydroxy-N'-Phenyl-octanediamide (Vorinostat) in Patients With Mild Alzheimer's Disease
Lead sponsor
German Center for Neurodegenerative Diseases (DZNE)
Phase
Phase 1
Overall status
Terminated
Start date
September 28, 2017
Completion date
March 4, 2024
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease